Follicular Lymphoma
Follicular Lymphoma
The latest news, research, and perspectives in follicular lymphoma (FL).
Advertisement
Stefano Luminari, MDAggressive B-Cell Lymphoma | October 3, 2024
The positive safety profile of this bispecific antibody makes it well-suited for combination with other treatments.
View More
Andrew MorenoFollicular Lymphoma | October 4, 2024
Encouraging efficacy and safety seen over 17 months in a phase II trial continued into the trial's 29-month follow-up period.
Melissa BadamoFollicular Lymphoma | August 26, 2024
The approval is based on results from the phase I ELM-1 and phase II ELM-2 trials.
Andrew MorenoFollicular Lymphoma | August 20, 2024
The conditional marketing authorization was given for use as monotherapy in adults after two or more lines of prior therapy.
Andrew MorenoTransplantation & Cellular Therapy | July 18, 2024
A phase II trial found antitumor effect across patient subgroups and independently of risk factors for disease progression.
Patrick DalyFollicular Lymphoma | October 4, 2024
Treatment with liso-cel was effective and safe in patients with relapsed or refractory follicular lymphoma in TRANSCEND FL.
Advertisement
Melissa BadamoFollicular Lymphoma | June 3, 2024
The median progression-free survival, duration of response, and overall survival were not reached.
Andrew MorenoFollicular Lymphoma | June 3, 2024
MRD is closely associated with disease control success during and after induction therapy in FL, trial analysis finds.
Patrick DalyFollicular Lymphoma | August 23, 2024
The US FDA has granted accelerated approval for liso-cel in adult patients with relapsed or refractory follicular lymphoma.
Patrick DalyFollicular Lymphoma | April 9, 2024
Tumor cells in high-risk follicular lymphoma had enhanced B-cell receptor signaling and distinct follicular growth patterns.
Melissa BadamoAggressive B-Cell Lymphoma | May 21, 2024
The approval was declined due to the enrollment status of the confirmatory trials.
Patrick DalyFollicular Lymphoma | March 7, 2024
Common adverse reactions to zanubrutinib observed across studies included decreased neutrophil and platelet counts.
Patrick DalyFollicular Lymphoma | March 7, 2024
Axi-cel yielded improved long-term outcomes versus conventional treatments in extended follow-up of the ZUMA-5 trial.
Melissa BadamoFollicular Lymphoma | February 16, 2024
At a median follow-up of 18.1 months, the ORR and CR rates were both 95.7% following liso-cel treatment.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | February 15, 2024
In episode four of the 2024 season, Dr. Coombs shares updates in CHIP from ASH 2023.
Patrick DalyMantle Cell Lymphoma | April 2, 2024
Liso-cel received regulatory acceptances from the US FDA and the Ministry of Health, Labour and Welfare in Japan for FL.
Leah SherwoodMyeloma | February 2, 2024
The agency's statement follows potential risks identified by the FDA Adverse Event Reporting System.
Patrick DalyFollicular Lymphoma | February 20, 2024
Epcoritamab yielded deep responses with promising response rates in high-risk relapsed or refractory follicular lymphoma.
Melissa BadamoIndolent B-Cell Lymphoma | February 2, 2024
The trial studied a fixed-duration regimen of mosunetuzumab plus lenalidomide in follicular lymphoma.
Melissa BadamoIndolent B-Cell Lymphoma | February 14, 2024
Among 26 response-evaluable patients, the best overall response rate was 96% and the complete response rate was 81%.
Advertisement
Advertisement
Editorial Board